Creo Medical Group (LON:CREO) Stock Passes Below 50-Day Moving Average – Should You Sell?

Creo Medical Group PLC (LON:CREO)’s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 13.90 and traded as low as GBX 13.03. Creo Medical Group shares last traded at GBX 13.44, with a volume of 166,113 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a report on Thursday, July 23rd.

Creo Medical Group Trading Up 1.9%

The stock has a market capitalization of £65.58 million, a P/E ratio of 13.50 and a beta of 1.62. The stock’s 50 day moving average price is GBX 13.90 and its 200-day moving average price is GBX 13.39. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20.

Creo Medical Group (LON:CREO) last issued its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) EPS for the quarter. The business had revenue of GBX 600 million during the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. As a group, equities research analysts expect that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Craig Jonathan Gulliford acquired 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average cost of GBX 14 per share, for a total transaction of £875. Also, insider Richard John Rees acquired 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average cost of GBX 14 per share, for a total transaction of £875. Company insiders own 6.92% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.